SEPT 25th – Become 1 of 1,806,000 New “Musk Millionaires” [How To Guide]

The question that moved markets Monday morning was framed as a regulatory one: will Washington keep the door open for US pharma companies to license drugs from China? The more uncomfortable version, the one worth sitting with, is whether that door was ever really up for debate.

Why Institutional Investors Are Paying Attention

Chinese biopharma stocks rose Monday after Reuters reported that the US may continue to allow most drug licensing deals with Chinese firms, while carving out restrictions for areas tied to pathogens or potential weapons applications. The Hang Seng Biotech Index climbed more than 5%. The rally tells you something about how much is riding on the outcome, but it doesn’t tell you the deeper story.

In the first half of 2026, Chinese companies accounted for eight of the world’s ten largest out-licensing deals, worth a record $110 billion, according to GlobalData. Those are not the numbers of a peripheral supplier. China is now the early-stage pipeline for much of Western pharma.

The Bull Case: The Carve-out Makes Commercial Sense

Big Pharma’s argument is straightforward: as blockbuster drugs lose exclusivity, companies need fresh pipelines, and Chinese biotech firms have become prolific sources of novel molecules and therapeutic platforms. Bristol Myers Squibb this year signed a partnership with Jiangsu Hengrui Pharma worth up to $15.2 billion, while Pfizer announced an up-to-$10.5 billion collaboration with Innovent Biologics covering 12 oncology programs. These are not marginal deals. They are pipeline strategy.

Big pharma faces a patent cliff that could strip away $300 billion, roughly a sixth of the industry’s overall revenue, by 2030, according to an Evaluate report. The specific pressure points are Merck’s Keytruda, BMS’s Eliquis and Opdivo, and Pfizer’s mature-product portfolio. Over the next five years, the companies under the greatest pressure are Merck, BMS, and Pfizer. For those three, China isn’t a geopolitical abstraction, it’s the fastest available replacement inventory.

The Bear Case: Dependency Has Costs That Don’t Show Up in Filings

Some lawmakers and smaller drugmakers are not on board with the carve-out approach, seeing such investment as a national-security risk that would undercut America’s lead role in developing medicines. Representative Moolenaar wrote to Treasury that “United States capital flowing to Chinese biotechnology companies through licensing agreements, joint ventures, and equity investments is fueling China’s strategy, aiding it in its rapid ascent up the pharmaceutical value chain.”

The US biopharmaceutical industry is mobilizing significant lobbying resources to preserve the ability to do licensing deals, even as policymakers debate expanding outbound-investment scrutiny. The fact that preserving the status quo requires that level of lobbying is itself informative. It suggests industry knows the regulatory environment could shift, and that the current arrangement is not structurally guaranteed.

What Investors Are Missing

The debate has been framed as a binary: restrictions or no restrictions. The more important question for healthcare portfolios is whether the dependence on Chinese-originated molecules has been underwritten or simply inherited.

Evidence shows how large pharmaceutical companies are no longer the primary source of drug innovation; they are increasingly its buyers. That shift happened gradually, driven by cost and speed rather than any explicit strategy. Chinese biotech firms, many operating with lower costs and faster clinical execution, are increasingly well placed to supply the novel molecules global companies need through licensing deals that can be cheaper and quicker than building replacements in-house.

China has made globalization a key goal for pharmaceutical and biotech companies under its 15th five-year plan. Washington may grant the carve-out. Beijing has its own terms for how long it lasts.

Stocks to Watch

Pfizer (PFE) and Bristol Myers Squibb (BMY) are the most directly exposed, each having committed more than $10 billion to Chinese partnerships this year alone while simultaneously navigating steep patent losses. A shift in the regulatory environment would hit pipeline timelines fast.

Merck (MRK) faces the most concentrated single-product cliff. Biosimilar competition to Keytruda could begin after the main compound patent expires in December 2028, and Keytruda accounted for 49% of Merck’s total revenue in 2025. Its China licensing activity is not a growth story, it is a survival calculation.

AstraZeneca (AZN) and GSK (GSK) face the same structural logic from the European side of the trade. AstraZeneca signed a deal for an experimental weight-loss portfolio with CSPC Pharmaceutical Group worth up to $18.5 billion, one of the largest transactions in the licensing boom. Any hardening of US rules would create secondary pressure on their ability to develop and commercialize those assets in American markets.

Treasury’s carve-out, if finalized, is good news for near-term deal flow. It is not a resolution of the underlying question: whether pharma companies built a durable pipeline strategy or just a convenient one.